SHJBF Stock Chart & Stats
$3.25
--
Market closed
$3.25
--
Day’s Range― - ―
52-Week Range$2.12 - $4.54
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.00
Market Cap
$4.83B
Enterprise Value$31.99B
Total Cash (Recent Filing)$4.55B
Total Debt (Recent Filing)$5.96B
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding260,295,700
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market Cap6.63
Enterprise Value/Revenue11.82
Enterprise Value/Gross Profit15.11
Enterprise Value/Ebitda-59.91
Forecast
1Y Price Target
$4.25Price Target Upside30.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$420.63M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 79% indicate strong product-level economics and pricing power for biologics. High unit economics improve the long-term scalability of sales, support reinvestment in R&D and commercialization, and provide a durable cushion as the company grows revenues.
Revenue Growth MomentumPositive top-line growth across reported periods shows expanding market adoption of marketed therapies and pipeline commercialization progress. Durable revenue growth helps close operating leverage gaps and supports future margin improvement if maintained through geographic or product expansion.
Focused R&D And Commercialization CapabilitiesA clear focus on immuno-oncology and both development and commercialization capabilities creates competitive advantages: internal manufacturing, clinical expertise and go-to-market capacity increase chances of converting pipeline assets to sustained revenue over the medium term.
Bears Say
Persistent UnprofitabilityMaterial and persistent operating losses (net margin ~-35%) limit retained earnings and weaken return metrics. Unless operating leverage improves, continued unprofitability threatens equity value, increases reliance on external capital and constrains long-term strategic flexibility.
Negative Operating And Free Cash FlowConsistent negative OCF and deeply negative FCF indicate the business consumes cash to fund operations and growth. This structural cash deficit necessitates external financing or asset sales, limiting the company's ability to self-fund R&D, commercialization or buffer against cyclical pressures.
Rising Leverage And Weak Returns On EquityHigher leverage combined with negative ROE reduces financial flexibility and increases interest and refinancing risk. If profitability does not recover, elevated leverage can amplify downside for shareholders and constrain strategic investments or partnership negotiating power.
Shanghai Junshi Biosciences Co., Ltd. Class H News
SHJBF FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was $2.12 and its highest was $4.54 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap is $4.83B.
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 42 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 260,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.439%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in SHJBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.51%
12-Months-Change
Fundamentals
Return on Equity
-10.78%
Trailing 12-Months
Asset Growth
37.38%
Trailing 12-Months
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases. Among its offerings is JS001, marketed as TUOYI, a recombinant humanized anti-PD-1 monoclonal antibody. This treatment is prescribed for a wide array of cancers, including melanoma (both cutaneous and mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. The company's development pipeline also includes UBP1211, a biosimilar version of Humira, intended for rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Additionally, they are advancing JS002, a recombinant humanized anti-PCSK9 monoclonal antibody designed to address hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Further projects encompass JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, which acts as a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, another injectable recombinant humanized anti-IL-17A monoclonal antibody. Furthermore, Junshi Biosciences holds partnerships, including an agreement with Eli Lilly and Company to collaboratively develop therapeutic antibodies aimed at the prevention and treatment of COVID-19, the illness resulting from the SARS-CoV-2 novel coronavirus. Another collaboration is with Coherus Biosciences, Inc. for the advancement and commercialization of toripalimab, which is Junshi Biosciences' anti-PD-1 antibody. Established in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its primary offices in Shanghai, People's Republic of China.
SHJBF Stock 12 Month Forecast
Average Price Target
$4.25
▲(30.76% Upside)
Innovent Biologics
―
Zai Lab Ltd
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
2.43% Mutual Funds
― Other Institutional Investors
95.81% Public Companies and
Individual Investors